Entero Therapeutics, Inc.

ENTO · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$1,153-$998-$1,260-$12,238
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$45
Change in WC$297$604$314$1,400
Other Non-Cash$0$339$127$10,622
Operating Cash Flow-$856-$55-$819-$172
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$336$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$336$0$0$0
Financing Activities
Debt Repay.$0$0$700-$32
Stock Issued$3,025$0$0$1,730
Stock Repurch.$0$0$0$0
Dividends Paid-$91-$163$0$0
Other Fin. Act.$91$163$0-$1,730
Financing Cash Flow$3,025$0$700-$32
Forex Effect$0$0$0$0
Net Chg. in Cash$2,506-$55-$119-$203
Supplemental Information
Beg. Cash$11$66$185$388
End Cash$2,517$11$66$185
Free Cash Flow-$856-$55-$819-$172
Entero Therapeutics, Inc. (ENTO) Financial Statements & Key Stats | AlphaPilot